evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
Published 1 year ago • 125 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
2:02
the evolving treatment landscape for urothelial cancer
-
2:05
the evolving treatment landscape of advanced and metastatic urothelial carcinoma
-
1:08
the future of enfortumab vedotin in different stages bladder cancer
-
1:58
enfortumab vedotin for the treatment of advanced urothelial cancer
-
1:18
the role of enfortumab vedotin in urothelial cancer treatment
-
4:16
unite: enfortumab vedotin in advanced urothelial cancer
-
1:15
what role will erdafitinib play in treating metastatic urothelial carcinoma?
-
1:47
the future role of erdafitinib in advanced urothelial carcinoma
-
1:59
how can we best sequence novel treatments in urothelial cancer?
-
0:34
enfortumab vedotin for urothelial cancer in the real-world setting
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
0:54
where do adcs fit in the treatment landscape of urothelial carcinoma?
-
0:47
expert highlights next steps to evolve the treatment landscape of urothelial cancer
-
1:08:04
understanding the evolving treatment landscape in bladder cancer
-
6:01
ev-201, ev-301 and unite: enfortumab vedotin in advanced urothelial cancer
-
6:09
enfortumab vedotin for previously-treated advanced urothelial carcinoma
-
2:58
ev-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
-
1:17
recent treatment approvals for metastatic and advanced urothelial carcinoma
-
2:12
erdafitinib: one more tool for bladder cancer